Literature DB >> 14698575

Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages.

S P Vyas1, M E Kannan, Sanyog Jain, V Mishra, Paramjit Singh.   

Abstract

The present study was aimed at preparation, characterization, and performance evaluation of rifampicin-loaded aerosolized liposomes for their selective presentation to alveolar macrophages, that being the most dense site of tuberculosis infection. Egg phosphatidylcholine (PC)- and cholesterol (Chol)-based liposomes were modified by imparting negative charge (using dicetylphosphate, DCP) or by coating them with alveolar macrophage-specific ligands (maleylated bovine serum albumin, MBSA; and O-steroyl amylopectin, O-SAP). The prepared formulations were characterized in vitro for vesicle morphology, mean vesicle size, and percent drug entrapment. Pressurized packed systems based on preformed liposomal formulations in chlorofluorocarbon aerosol propellants were prepared. In vitro airway penetration efficiency of the liposomal aerosols was determined by percent dose reaching the base of the lung, it was recorded 1.5-1.8 times higher as compared to plain drug solution-based aerosol. Percent viability of Mycobacterium smegmatis inside macrophages (in vitro) after administration of drug (in vivo) was in the range of 7-11% in the case of ligand-anchored liposomal aerosols, while it was recorded to be 45.7 and 31.6% in case of plain drug and plain neutral liposomal aerosol (based on PC:Chol)-treated macrophages. Results suggest the preferential accumulation of MBSA- and O-SAP-coated formulations in the lung macrophages, which was further reflected in the periodically monitored in vivo tissue distribution studies. Higher lung drug concentration was recorded in case of ligand-anchored liposomal aerosols and negatively charged liposomal aerosols (based on PC:Chol:DCP) as compared to plain drug and plain liposome-based aerosols. The drug was estimated in the lung in high concentration even after 24h. The drug localization index calculated after 6h was nearly 1.4- and 3.5-fold, respectively, for both ligand-appended liposome-based systems as compared to negatively charged and plain neutral liposome-based aerosolized systems. These results suggest that the ligand-anchored liposomal aerosols are not only effective in rapid attainment of high-drug concentration in lung with high population of alveolar macrophages but also maintain the same over prolonged period of time. The significance of targeting potential of the developed systems was established.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14698575     DOI: 10.1016/j.ijpharm.2003.08.017

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  36 in total

Review 1.  Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

Authors:  Lauren Willis; Don Hayes; Heidi M Mansour
Journal:  Lung       Date:  2012-01-25       Impact factor: 2.584

2.  Polymer-augmented liposomes enhancing antibiotic delivery against intracellular infections.

Authors:  Fang-Yi Su; Jasmin Chen; Hye-Nam Son; Abby M Kelly; Anthony J Convertine; T Eoin West; Shawn J Skerrett; Daniel M Ratner; Patrick S Stayton
Journal:  Biomater Sci       Date:  2018-06-25       Impact factor: 6.843

3.  Biodistribution and histopathology studies of amphotericin B sodium deoxycholate sulfate formulation following intratracheal instillation in rat models.

Authors:  Faisal Usman; Jongdee Nopparat; Ibrahim Javed; Teerapol Srichana
Journal:  Drug Deliv Transl Res       Date:  2020-02       Impact factor: 4.617

Review 4.  Inhaled drug delivery for tuberculosis therapy.

Authors:  Pavan Muttil; Chenchen Wang; Anthony J Hickey
Journal:  Pharm Res       Date:  2009-11       Impact factor: 4.200

5.  Soft particle analysis of electrokinetics of biological cells and their model systems.

Authors:  Kimiko Makino; Hiroyuki Ohshima
Journal:  Sci Technol Adv Mater       Date:  2011-04-26       Impact factor: 8.090

6.  Rifampicin loaded mannosylated cationic nanostructured lipid carriers for alveolar macrophage-specific delivery.

Authors:  Xu Song; Qing Lin; Ling Guo; Yao Fu; Jianfeng Han; Huan Ke; Xun Sun; Tao Gong; Zhirong Zhang
Journal:  Pharm Res       Date:  2014-11-19       Impact factor: 4.200

Review 7.  Synthetic nanovaccines for immunotherapy.

Authors:  Min Luo; Layla Z Samandi; Zhaohui Wang; Zhijian J Chen; Jinming Gao
Journal:  J Control Release       Date:  2017-03-21       Impact factor: 9.776

8.  Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles.

Authors:  Takuto Mizoe; Tetsuya Ozeki; Hiroaki Okada
Journal:  AAPS PharmSciTech       Date:  2008-06-18       Impact factor: 3.246

9.  In Vitro Investigation of Influences of Chitosan Nanoparticles on Fluorescein Permeation into Alveolar Macrophages.

Authors:  Siti Haziyah Mohd Chachuli; Asif Nawaz; Kifayatullah Shah; Idanawati Naharudin; Tin Wui Wong
Journal:  Pharm Res       Date:  2016-03-07       Impact factor: 4.200

Review 10.  Nanomedicine in pulmonary delivery.

Authors:  Heidi M Mansour; Yun-Seok Rhee; Xiao Wu
Journal:  Int J Nanomedicine       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.